The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2019 | Rationale for NK-cell therapy in myeloma
Here, Michael O’Dwyer, MD, PhD, from the National University of Ireland, Galway, Ireland, discusses the importance of fully functional NK-cells, which mediate antibody-dependant cytotoxicity, in multiple myeloma. At the Controversies in Multiple Myeloma (COMy) 2019 World Congress in Paris, France, Prof. O’Dwyer also speaks of the challenges of CAR T-cell administration as a therapy, and how anti-CD38 CAR NK-cells could selectively target myeloma cells.
